Nan Fung Trinity HK Ltd. Has $11.46 Million Position in Mirum Pharmaceuticals, Inc. $MIRM

Nan Fung Trinity HK Ltd. raised its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 6.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 156,265 shares of the company’s stock after buying an additional 9,500 shares during the quarter. Nan Fung Trinity HK Ltd. owned 0.31% of Mirum Pharmaceuticals worth $11,456,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Comerica Bank boosted its position in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the period. CWM LLC boosted its holdings in Mirum Pharmaceuticals by 30.8% in the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after purchasing an additional 161 shares during the period. Osaic Holdings Inc. grew its position in shares of Mirum Pharmaceuticals by 46.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock worth $56,000 after purchasing an additional 351 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Mirum Pharmaceuticals by 14.9% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,914 shares of the company’s stock worth $97,000 after purchasing an additional 248 shares during the period. Finally, Hollencrest Capital Management acquired a new stake in shares of Mirum Pharmaceuticals in the third quarter valued at approximately $138,000.

Analysts Set New Price Targets

A number of equities analysts have commented on MIRM shares. Wall Street Zen upgraded Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. Stifel Nicolaus increased their target price on Mirum Pharmaceuticals from $92.00 to $98.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Morgan Stanley raised their price target on Mirum Pharmaceuticals from $95.00 to $123.00 and gave the stock an “overweight” rating in a research report on Friday. Evercore ISI reaffirmed an “outperform” rating and set a $101.00 price objective on shares of Mirum Pharmaceuticals in a research report on Tuesday, January 20th. Finally, Raymond James Financial reissued a “strong-buy” rating and issued a $110.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $107.25.

Insider Activity at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 3,143 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $96.19, for a total value of $302,325.17. Following the completion of the transaction, the chief operating officer owned 23,286 shares of the company’s stock, valued at $2,239,880.34. This represents a 11.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Eric Bjerkholt sold 1,421 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $93.33, for a total transaction of $132,621.93. Following the completion of the transaction, the chief financial officer owned 42,127 shares of the company’s stock, valued at approximately $3,931,712.91. This trade represents a 3.26% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 32,429 shares of company stock valued at $3,039,396. 14.36% of the stock is owned by company insiders.

Mirum Pharmaceuticals Stock Performance

Mirum Pharmaceuticals stock opened at $103.22 on Friday. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. The stock has a market cap of $5.30 billion, a PE ratio of -120.02 and a beta of 0.48. Mirum Pharmaceuticals, Inc. has a 12-month low of $36.88 and a 12-month high of $103.81. The business’s 50-day moving average price is $80.29 and its two-hundred day moving average price is $72.31.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. The company had revenue of $133.01 million for the quarter, compared to the consensus estimate of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The firm’s quarterly revenue was up 47.1% compared to the same quarter last year. During the same period last year, the company posted ($0.30) EPS. As a group, analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.